Thursday, May 11, 2023 11:25:59 AM
earnings were not a surprise but it was expected. the closer we get to fda approval the more the stock will advance, you will see profit taking along the way. some could clearly trade in and out on this but just don't miss the major leg up. good luck
Bullish
Recent SMMT News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/17/2026 09:00:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/17/2026 08:12:22 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/06/2026 08:28:53 PM
- Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 • Business Wire • 03/27/2026 12:15:00 PM
- Summit Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 02/26/2026 11:45:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2026 09:58:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/23/2026 09:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:07:53 PM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 • Business Wire • 02/23/2026 09:05:00 PM
- Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 • Business Wire • 02/17/2026 10:05:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/30/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:35:03 PM
- Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy • Business Wire • 01/29/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2026 09:01:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 12:43:04 PM
- Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) • Business Wire • 01/12/2026 11:15:00 AM
- Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC • Business Wire • 01/12/2026 11:00:00 AM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/10/2026 01:16:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 11:52:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 11:39:57 PM
- Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference • Business Wire • 01/06/2026 12:30:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/05/2025 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 02:23:15 PM
- Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China • Business Wire • 11/07/2025 02:00:00 PM
- Summit Therapeutics to Present at Upcoming Investor Conferences • Business Wire • 11/04/2025 12:00:00 PM
